TABLE 2.
Presence of antibiotic resistance genes in clinical carbapenemase-positive and carbapenemase-negative CR-EC isolates.
| Carbapenem resistance mechanisms | Total (109) | Carbapenemase positive (50) | Carbapenemase negative (59) | |
| Carbapenemase type(s) | 50(45.9%) | |||
| NDM- positive | NDM-1 | 8(7.3%) | 8(16.0%) | NA |
| NDM-5 | 41(37.6%) | 41(82.0%) | ||
| NDM-9 | 1(0.9%) | 1(2.0%) | ||
| KPC- positive | KPC-2 | 1(0.9%) | 1(2.0%) | NA |
| NDM-5, KPC-2 | 1(0.9%) | 1(2.0%) | NA | |
| ESBL type(s) | 83(76.2%) | |||
| CTXM- positive | CTXM-1 | 46(42.2%) | 24(48.0%) | 22 (37.3%) |
| CTXM-9 | 25(22.9%) | 16(32.0%) | 9 (15.3%) | |
| CTXM-15 | 23(21.1%) | 16(32.0%) | 7 (11.9%) | |
| TEM- positive | TEM-1 | 35(32.1%) | 29(58.0%) | 6 (10.2%) |
| OXA-1-positive | OXA-1 | 23(21.1%) | 8(16.0%) | 15 (25.4%) |
| OMPs loss | 32(29.4%) | |||
| OMPs | OmpC | 27(24.8%) | 12(24.0%) | 15 (25.4%) |
| OmpF | 21(19.3%) | 11(22.0%) | 10 (16.9%) | |
| OmpC, OmpF | 16(14.7%) | 4(8.0%) | 12 (20.3%) | |
| Carbapenemase, ESBL type | 50(45.9%) | 50(100.0%) | NA | |
| Carbapenemase, ESBL type, OMPs loss | 12(11.0%) | 12(24.0%) | NA | |
| Carbapenemase, OMPs loss | 12(11.0%) | 12(24.0%) | NA | |
| ESBL type, OMPs loss | 27(24.8%) | 12(24.0%) | 15 (25.4%) | |
NA, not applicable.